Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, non-colorectal 2

2538 - Genomic profiling of small bowel adenocarcinoma: Insights from a comparative analysis with gastric and colorectal cancer and opportunities for targeted therapy


09 Oct 2016


Gastrointestinal tumours, non-colorectal 2


Michael Overman


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


M.J. Overman1, A.B. Schrock2, C.E. Devoe3, R. McWilliams4, J. Sun5, J.T. Ruggiero6, P. Stephens7, J.S. Ross8, R. Wilson9, V.A. Miller10, S.M. Ali10

Author affiliations

  • 1 Gastrointestinal Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 2 Clinical Development, Foundation Medicine, Inc., 02141 - Cambridge/US
  • 3 Northwell Health, The Monter Cancer Cencer, Lake Success/US
  • 4 Medical Oncology, Mayo Clinic, Rochester/US
  • 5 Biomarker Development, Foundation Medicine, Inc., Cambridge/US
  • 6 Medical Oncology, Weill Cornell Medical College, New York/US
  • 7 Clinical Genomics, Foundation Medicine, Inc., 02141 - Cambridge/US
  • 8 Pathology, Foundation Medicine, Inc., Cambridge/US
  • 9 Centre For Cancer Research And Cell Biology, Queen's University Belfast, BT9 7JL - Belfast/GB
  • 10 Clinical Development, Foundation Medicine, Inc., Cambridge/US


Abstract 2538


Small bowel adenocarcinomas (SBAs) are rare cancers with significantly lower incidence, later stage at diagnosis, and worse overall survival than other intestinal derived cancers including colorectal cancer (CRC). To date, comprehensive genomic characterization and identification of targetable genomic alterations in SBA is lacking.


We prospectively analyzed clinical samples from 358 patients with SBA, 6,353 patients with CRC, and 889 patients with gastric carcinoma (GC) using hybrid-capture based comprehensive genomic profiling (CGP).


We compared available clinical features and complete molecular profiles for SBA, CRC and GC patients. In all three series the majority were male (52-55%) and SBA patients tended to be marginally older (median 60 years old). APC alterations were less frequent in SBA (27%) than in CRC (76%) (P 


This study presents the first large scale genomic comparison of SBA with CRC and GC, as well as a comparison of unspecified SBAs with tumors of the duodenum. Higher incidence of microsattelite instability in SBA suggests that an important subset of these patients may benefit from treatment with anti-PD-1/PD-L1 therapies. The use of CGP during the course of clinical care identifies targetable genomic alterations across intestinal tumor types and allows patients to be matched with appropriate targeted therapies.

Clinical trial identification

Legal entity responsible for the study

Foundation Medicine, Inc.


Foundation Medicine, Inc.


A.B. Schrock, J. Sun, P. Stephens, J.S. Ross, V.A. Miller, S.M. Ali: Employee at Foundation Medicine. Stock ownership: Foundation Medicine. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings